Submitted by: Amy L. on Tue, 12/07/2021

Hi Glen. We remain committed to advocating for approval of all treatments that are proven safe and effective based on peer-reviewed data. In phase 2, NurOwn met its primary endpoint for safety but was not powered to assess efficacy. Its phase 3 trial was designed to prove efficacy, but it did not meet its primary and secondary endpoints.

CAPTCHA
15 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.